Lucid Diagnostics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Lucid Diagnostics Stock-Based Compensation Growth & History (LUCD)
Lucid Diagnostics's stock-based compensation was $4.5M for fiscal 2025.
View full Lucid Diagnostics company overviewLucid Diagnostics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.5M | $308,000 | +7.36% |
| 2024 | 2024-12-31 | $4.2M | −$1.6M | −27.40% |
| 2023 | 2023-12-31 | $5.8M | −$8.1M | −58.42% |
| 2022 | 2022-12-31 | $13.9M | $4.7M | +51.73% |
| 2021 | 2021-12-31 | $9.1M | $9.1M | +13952.31% |
| 2020 | 2020-12-31 | $65,000 | — | — |
Lucid Diagnostics quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.7M | $551,000 | +48.21% |
| Q1 2026 | 2026-03-31 | $1.4M | $462,000 | +48.68% |
| Q4 2025 | 2025-12-31 | $1.3M | $115,000 | +10.01% |
| Q3 2025 | 2025-09-30 | $1.1M | −$49,000 | −4.14% |
| Q2 2025 | 2025-06-30 | $1.1M | $36,000 | +3.25% |
| Q1 2025 | 2025-03-31 | $949,000 | $206,000 | +27.73% |
| Q4 2024 | 2024-12-31 | $1.1M | $401,000 | +53.61% |
| Q3 2024 | 2024-09-30 | $1.2M | $152,000 | +14.73% |
| Q2 2024 | 2024-06-30 | $1.1M | −$58,000 | −4.98% |
| Q1 2024 | 2024-03-31 | $743,000 | −$2.1M | −73.62% |
| Q4 2023 | 2023-12-31 | $748,000 | −$2.5M | −76.62% |
| Q3 2023 | 2023-09-30 | $1.0M | −$2.2M | −68.54% |
| Q2 2023 | 2023-06-30 | $1.2M | −$2.7M | −69.69% |
| Q1 2023 | 2023-03-31 | $2.8M | −$720,000 | −20.36% |
| Q4 2022 | 2022-12-31 | $3.2M | $222,202 | +7.46% |
| Q3 2022 | 2022-09-30 | $3.3M | $507,798 | +18.32% |
| Q2 2022 | 2022-06-30 | $3.8M | $1.3M | +48.95% |
| Q1 2022 | 2022-03-31 | $3.5M | $2.7M | +339.38% |
| Q4 2021 | 2021-12-31 | $3.0M | — | — |
| Q3 2021 | 2021-09-30 | $2.8M | $2.8M | +16839.82% |
| Q2 2021 | 2021-06-30 | $2.6M | — | — |
| Q1 2021 | 2021-03-31 | $805,000 | — | — |
| Q3 2020 | 2020-09-30 | $16,365 | — | — |
Lucid Diagnostics stock-based compensation trends
Over the last five fiscal years, Lucid Diagnostics's stock-based compensation increased from $65,000 to $4.5M, a change of $4.4M. The latest reported quarter, Q2 2026, shows $1.7M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lucid Diagnostics source filings ↗